CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers-Reference-Cited by-同舟云学术

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers

Published:2017-06-27 Issue:1 Volume:8 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Vijayaraghavan Smruthi^ORCID,Karakas Cansu,Doostan Iman,Chen Xian,Bui Tuyen,Yi Min,Raghavendra Akshara S.,Zhao Yang^ORCID,Bashour Sami I.,Ibrahim Nuhad K.,Karuturi Meghan,Wang Jing,Winkler Jeffrey D.,Amaravadi Ravi K.,Hunt Kelly K.,Tripathy Debu,Keyomarsi Khandan

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms15916.pdf

Reference70 articles.

1. O'Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4/6 inhibitors. Nat. Rev. Clin. Oncol. 13, 417–430 (2016).

2. Finn, R. S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25–35 (2015).

3. Finn, R. S. et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer. J. Clin. Oncol. 34, (suppl): abstr 507 (2016).

4. Turner, N. C. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209–219 (2015).

5. Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6, 353–367 (2016).

Cited by 207 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

2. Risk factors of using late-autophagy inhibitors: Aspects to consider when combined with anticancer therapies;Biochemical Pharmacology;2024-07

3. Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells;Cancer Immunology, Immunotherapy;2024-05-02

4. Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review;Breast Cancer: Targets and Therapy;2024-04

5. Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer;Frontiers in Endocrinology;2024-03-18